General management plan

Graves' Orbitopathy: A Multidisciplinary Approach - Questions and Answers

Volumn , Issue , 2010, Pages 88-95

  Boboridis, K ^a   Perros, Dr ^b  

^a PANAGIA GENERAL HOSPITAL   (Greece)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882075357     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000320431     Document Type: Chapter

References (28)

1. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, KendallTaylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, MarinÒ M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM: Consensus statement of the European Group on Graveś orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158: 273-285.
2. Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, KendallTaylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini MS, Stahl M, von Arx G: Clinical assessment of patients with Graveś orbitopathy: the European Group on Graveś Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 2006;155:387-389.
3. Prummel MF, Wiersinga WM: Smoking and risk of Graveś disease. J Am Med Assoc 1993;269:479-482.
4. Pfeilschifter J, Ziegler R: Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs. lifetime cigarette consumption. Clin Endocrinol (Oxf) 1996;45:477-481.
5. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A: Cigarette smoking and treatment outcomes in Graveś ophthalmopathy. Ann Intern Med 1998;129:632-635.
6. Eckstein A, Quadbeck B, Mueller G, Rettenmeier AW, Hoermann R, Mann K, Steuhl P, Esser J: Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 2003; 87:773-776.
7. Krassas GE, Wiersinga W: Smoking and autoimmune thyroid disease: the plot thickens. Eur J Endocrinol 2006;154:777-780.
8. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R: Amelioration of eye changes of Graveś ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 1989;121(suppl 2):185-189.
9. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R: Effect of abnormal thyroid function on the severity of Graveś ophthalmopathy. Arch Intern Med 1990;150:1098-1101.
10. Kim JM, LaBree L, Levin L, Feldon SE: The relation of Graveś ophthalmopathy to circulating thyroid hormone status. Br J Ophthalmol 2004;88:72-74.
11. Karlsson F, Westermark K, Dahlberg PA, Jansson R, Enoksson P: Ophthalmopathy and thyroid stimulation. Lancet 1989;ii:691.
12. Tallstedt L, Lundell G, Blomgren H, Bring J: Does early administration of thyroxine reduce the development of Graveś ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994;130:494-497.
13. Perros P, KendallTaylor P, Neoh C, Frewin S, Dickinson J: A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graveś ophthalmopathy. J Clin Endocrinol Metab 2005;90:5321-5323.
14. Eckstein AK, Finkenrath A, Heiligenhaus A, RenzingKohler K, Esser J, Kruger C, Quadbeck B, Steuhl KP, Gieseler RK: Dry eye syndrome in thyroidassociated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHRspecific autoantibodies. Acta Ophthalmol Scand 2004;82:291-297.
15. Gilbard JP, Farris RL: Ocular surface drying and tear film osmolarity in thyroid eye disease. Acta Ophthalmol (Copenh) 1983;61:108-116.
16. Baudouin C: Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008;86:716-726.
17. Haddad HM: Lid retraction therapy with a guanethidine solution. Arch Ophthalmol 1989;107:169.
18. Behrouzi Z, Rabei HM, Azizi F, Daftarian N, Mehrabi Y, Ardeshiri M, et al: Prevalence of openangle glaucoma, glaucoma suspect, and ocular hypertension in thyroidrelated immune orbitopathy. J Glaucoma 2007;16:358-362.
19. Uddin JM, Davies PD: Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology 2002;109:1183-1187.
20. Kikkawa DO, Cruz RC Jr, Christian WK, Rikkers S, Weinreb RN, Levi L, Granet DB: Botulinum A toxin injection for restrictive myopathy of thyroidrelated orbitopathy: effects on intraocular pressure. Am J Ophthalmol 2003;135:427-431.
21. Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N: A multicenter, doubleblind, randomized, placebocontrolled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002;46:840-849.
22. Bartalena L, Pinchera A, Marcocci C: Management of Graveś ophthalmopathy: reality and perspectives. Endocr Rev 2000;21:168-199.
23. Perros P, Crombie AL, KendallTaylor P: Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995;42:45-50.
24. Wiersinga WM, Prummel MF: Graveś ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab 2002;13:280-287.
25. Bartalena L, Marcocci C, Tanda ML, Piantanida E, Lai A, Marino M, Pinchera A: An update on medical management of Graveś ophthalmopathy. J Endocrinol Invest 2005;28:469-478.
26. Abramoff MD, Kalmann R, de Graaf ME, Stilma JS, Mourits MP: Rectus extraocular muscle paths and decompression surgery for Graves orbitopathy: mechanism of motility disturbances. Invest Ophthalmol Vis Sci 2002;43:300-307.
27. Fenton S, Kemp EG: A review of the outcome of upper lid lowering for eyelid retraction and complications of spacers at a single unit over five years. Orbit 2002;21:289-294.
28. Shorr N, Seiff SR: The four stages of surgical rehabilitation of the patient with dysthyroid ophthalmopathy. Ophthalmology 1986;93:476-483.